Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus
Status:
Not yet recruiting
Trial end date:
2028-01-04
Target enrollment:
Participant gender:
Summary
This project is aiming to better understand the use of perampanel as an appropriate
standard-of-care therapy for treatment refractory status epilepticus (RSE), to identify
determinants of outcomes, and establish safety. The study will recruit 25 patients at WSU.
The study will last for about 96 weeks and will involve a screening visit and two in clinic
visits at 3 and 6 months. If the subjects give written informed consent and meet all
eligibility criteria they will be clinically evaluated and will be given the study drug. This
study will involve recording of patients medical history, drug history and epilepsy history.
A physical exam and a and neurological exam will also be performed to study the heath status
of the participant. Results and patient information will be stored in a database for analysis
to find commonality among key factors that have been seen in past research.